MedTrace Logo

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

NCT02375685 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2020-01-03

No results posted yet for this study

Summary

The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm treatment with gevokizumab.

Conditions

  • Chronic Uveitis

Interventions

BIOLOGICAL

Gevokizumab

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Australia
  • Austria
  • France
  • Germany
  • Greece
  • Italy
  • Portugal
  • South Korea
  • Spain
  • Taiwan
  • Tunisia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02375685 on ClinicalTrials.gov